Macquarie Group’s NovoCure NVCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-13,250
| Closed | -$214K | – | 1667 |
|
|
2023
Q3 | $214K | Sell |
13,250
-1,638
| -11% | -$47.2K | ﹤0.01% | 1519 |
|
|
2023
Q2 | $618K | Sell |
14,888
-7,406
| -33% | -$460K | ﹤0.01% | 1433 |
|
|
2023
Q1 | $1.34M | Sell |
22,294
-57,955
| -72% | -$4.63M | ﹤0.01% | 1290 |
|
|
2022
Q4 | $5.89M | Buy |
80,249
+9,386
| +13% | +$706K | 0.01% | 952 |
|
|
2022
Q3 | $5.38M | Buy |
70,863
+22,142
| +45% | +$1.73M | 0.01% | 973 |
|
|
2022
Q2 | $3.39M | Sell |
48,721
-40,399
| -45% | -$3.04M | ﹤0.01% | 1139 |
|
|
2022
Q1 | $7.38K | Sell |
89,120
-314,295
| -78% | -$23.2M | 0.01% | 1011 |
|
|
2021
Q4 | $30.3M | Sell |
403,415
-267,112
| -40% | -$26.8M | 0.03% | 643 |
|
|
2021
Q3 | $77.9M | Sell |
670,527
-241,663
| -26% | -$36.5M | 0.07% | 382 |
|
|
2021
Q2 | $202M | Buy |
912,190
+208,856
| +30% | +$40.6M | 0.17% | 137 |
|
|
2021
Q1 | $93M | Sell |
703,334
-488,162
| -41% | -$77.2M | 0.13% | 175 |
|
|
2020
Q4 | $206M | Sell |
1,191,496
-323,259
| -21% | -$44.2M | 0.3% | 61 |
|
|
2020
Q3 | $169M | Buy |
1,514,755
+573,853
| +61% | +$45.9M | 0.29% | 62 |
|
|
2020
Q2 | $55.8M | Sell |
940,902
-365,543
| -28% | -$24M | 0.1% | 231 |
|
|
2020
Q1 | $88M | Buy |
1,306,445
+321,487
| +33% | +$25.4M | 0.18% | 100 |
|
|
2019
Q4 | $83M | Buy |
984,958
+11,279
| +1% | +$910K | 0.12% | 158 |
|
|
2019
Q3 | $72.8M | Sell |
973,679
-335,541
| -26% | -$26.8M | 0.12% | 162 |
|
|
2019
Q2 | $82.8M | Buy |
1,309,220
+146,726
| +13% | +$7.43M | 0.14% | 138 |
|
|
2019
Q1 | $56M | Sell |
1,162,494
-62,981
| -5% | -$3.03M | 0.1% | 222 |
|
|
2018
Q4 | $41M | Buy |
1,225,475
+121,358
| +11% | +$4.44M | 0.08% | 265 |
|
|
2018
Q3 | $57.9M | Buy |
1,104,117
+519,988
| +89% | +$20.7M | 0.09% | 224 |
|
|
2018
Q2 | $18.3M | Buy |
584,129
+506,526
| +653% | +$14.1M | 0.03% | 499 |
|
|
2018
Q1 | $1.69M | Buy |
77,603
+7,537
| +11% | +$162K | ﹤0.01% | 1035 |
|
|
2017
Q4 | $1.42M | Buy |
70,066
+19,606
| +39% | +$378K | ﹤0.01% | 1131 |
|
|
2017
Q3 | $1M | Sell |
50,460
-16,882
| -25% | -$332K | ﹤0.01% | 1210 |
|
|
2017
Q2 | $1.17M | Sell |
67,342
-28,035
| -29% | -$362K | ﹤0.01% | 1122 |
|
|
2017
Q1 | $773K | Sell |
95,377
-2,710
| -3% | -$19.6K | ﹤0.01% | 1237 |
|
|
2016
Q4 | $770K | Buy |
98,087
+15,218
| +18% | +$122K | ﹤0.01% | 1232 |
|
|
2016
Q3 | $708K | Sell |
82,869
-68,425
| -45% | -$624K | ﹤0.01% | 1231 |
|
|
2016
Q2 | $1.77M | Buy |
+151,294
| New | +$1.89M | ﹤0.01% | 1172 |
|
Other funds holding NVCR
Macquarie Group's NVCR Position: Q4 2023 in Review
Macquarie Group sold out of NovoCure (NVCR) in Q4 2023, closing a stake of 13,250 shares — an estimated $214K sold.
Macquarie Group first reported a position in NVCR in Q2 2016 and held it in 30 quarters. The position peaked at $206M in Q4 2020. 219 funds tracked by Wall St. Rank hold NVCR as of Q4 2023.
- Macquarie Group reported no remaining NovoCure position as of Q4 2023 after selling out during the quarter.
- Macquarie Group sold 13,250 NovoCure shares in Q4 2023, an estimated $214K.
- Macquarie Group first reported a position in NovoCure in Q2 2016 and held it in 30 quarters.
- Macquarie Group's NovoCure position peaked at $206M in Q4 2020.
- 219 funds tracked by Wall St. Rank held NovoCure as of Q4 2023.
Based on Macquarie Group's 13F filing for Q4 2023, filed 14 Feb 2024.